Enzo Biochem, Inc. v. Gen-Probe, Inc.

414 F.3d 1376, 75 U.S.P.Q. 2d (BNA) 1602, 2005 U.S. App. LEXIS 14084
CourtCourt of Appeals for the Federal Circuit
DecidedJuly 13, 2005
Docket2004-1570
StatusPublished

This text of 414 F.3d 1376 (Enzo Biochem, Inc. v. Gen-Probe, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Enzo Biochem, Inc. v. Gen-Probe, Inc., 414 F.3d 1376, 75 U.S.P.Q. 2d (BNA) 1602, 2005 U.S. App. LEXIS 14084 (Fed. Cir. 2005).

Opinion

LOURIE, Circuit Judge.

Enzo Biochem, Inc. (“Enzo”) appeals from the summary judgment of the United States District Court for the Southern District of New York holding, on the motion of Gen-Probe, Incorporated and Becton Dickinson and Company (collectively, “Gen-Probe”), that United States Patent 4,900,659 is invalid under the on-sale bar of 35 U.S.C. § 102(b). Enzo Biochem, Inc. v. Gen-Probe, Inc., No. 99 Civ. 3548 (S.D.N.Y. July 27, 2004) (“Order”). Because Gen-Probe’s unenforceability counterclaim remains unadjudicated in the district court, the present appeal is not from a final decision within the meaning of 28 U.S.C. § 1295(a)(1). Therefore, this court lacks jurisdiction and we dismiss the instant appeal subject to reinstatement under the conditions set forth herein below.

BACKGROUND

Enzo is the assignee of the ’659 patent, which relates to nucleic acid probes that selectively hybridize to the bacteria that cause gonorrhea, namely, Neisseria gonor- *1378 rhoeae, as well as methods for using those probes to detect the bacteria. Enzo returns to this court seeking review of the district court’s decision following remand of its prior appeal focusing on the written description requirement of 35 U.S.C. § 112. See Enzo Biochem, Inc. v. Gen-Probe Inc., 323 F.3d 956 (Fed.Cir.2002). Upon remand, the district court considered Gen-Probe’s motion for summary judgment of invalidity on different grounds, including the on-sale bar of § 102(b).

In a detailed oral hearing conducted on July 27, 2004, the district court delivered its decision invalidating the ’659 patent for violating the on-sale bar. The trial judge specifically held that “there are no triable issues of fact,” and he granted defendants’ motion for summary judgment. Enzo Bio-chem, Inc. v. Gen-Probe, Inc., No. 99 Civ. 3548, at 34 (S.D.N.Y. July 27, 2004) (“Summary Judgment Hearing”). He made it clear that his rulings affected all six claims of the patent and held them invalid. Id.

Importantly, the trial judge concluded the hearing by asking the parties “if there is anything that I have missed in my rulings that I should rule upon.” Id. Both counsel responded that the court had covered all the issues raised, and Enzo’s counsel indicated that it would appeal the decision. Id. at 34-35. The judge then stated that he would “enter a summary order ... that will enable you to proceed with dispatch in the Federal Court of Appeals on your rights if I have erred.” Id. at 35. On July 29, 2004, the clerk of the district court entered judgment under Federal Rule of Civil Procedure 58 holding that all claims of the ’659 patent were invalid and that “the case was closed.”

Enzo filed a Notice of Appeal on August 20, 2004. Gen-Probe then moved to dismiss the appeal, arguing that its remaining unadjudicated counterclaim of unenforce-ability for inequitable conduct rendered the district court’s judgment nonfinal.

DISCUSSION

Our first order of business on this appeal is the question of finality, and hence our own jurisdiction. “Whether this court has jurisdiction over an appeal taken from a district court is a question of law which we address in the first instance.” Pause Tech. LLC v. TiVo Inc., 401 F.3d 1290, 1292 (Fed.Cir.2005). “[E]very federal appellate court has a special obligation to satisfy itself ... of its own jurisdiction .... ” Bender v. Williamsport Area Sch. Dist., 475 U.S. 534, 541, 106 S.Ct. 1326, 89 L.Ed.2d 501 (1986) (internal quotation omitted). We have specifically stated that “we are obligated to consider whether there is a final judgment of the district court.” Pandrol USA, LP v. Airboss Ry. Prods., 320 F.3d 1354, 1362 (Fed.Cir.2003). Under the final judgment rule, parties may appeal only a “final decision of a district court.” 28 U.S.C. § 1295(a)(1) (2000). That final judgment rule exists to prevent the piecemeal litigation of issues that practically constitute a single controversy, which as separate appeals would otherwise frustrate efficient judicial administration, see Firestone Tire & Rubber Co. v. Risjord, 449 U.S. 368, 374, 101 S.Ct. 669, 66 L.Ed.2d 571 (1981); Cobbledick v. United States, 309 U.S. 323, 325, 60 S.Ct. 540, 84 L.Ed. 783 (1940); Nystrom v. TREX Co., 339 F.3d 1347, 1350 (Fed.Cir.2003). The Supreme Court has defined a final judgment as a decision by a district court that “ends the litigation on the merits and leaves nothing to do but execute the judgment.” Catlin v. United States, 324 U.S. 229, 233, 65 S.Ct. 631, 89 L.Ed. 911 (1945).

Recently, we had occasion to review an appeal with a similar jurisdictional defect, Pause Technology LLC v. TiVo Inc. The issue there was whether an unresolved counterclaim still pending in the district court renders a judgment nonfinal and thus prevents this court from properly ex *1379 ercising jurisdiction over the appeal. In that case, we stated that, although “[t]here are cases in which the Supreme Court found appellate jurisdiction despite an alleged technical defect in the judgment ... none of those cases deals with a circumstance in which a claim or counterclaim remains unadjudicated.” 401 F.3d at 1295. Furthermore, we stated that those cases “also do not stand for the proposition that an appellate court can deem remaining claims impliedly dismissed.” Id.

In the present case, Gen-Probe argues that there was no final judgment in this case, and indeed, there was no adjudication of Gen-Probe’s unenforceability counterclaim, nor has Gen-Probe agreed to a dismissal without prejudice or without a finding of mootness. The district court also did not expressly find that the counterclaim was moot in light of its summary judgment of invalidity. Clearly, Gen-Probe’s counterclaim that Enzo’s ’659 patent is unenforceable remains unadjudicat-ed.

Nevertheless, Enzo alleges that the appeal is still ripe essentially for two principal reasons.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cobbledick v. United States
309 U.S. 323 (Supreme Court, 1940)
Catlin v. United States
324 U.S. 229 (Supreme Court, 1945)
United States v. F. & M. Schaefer Brewing Co.
356 U.S. 227 (Supreme Court, 1958)
Firestone Tire & Rubber Co. v. Risjord
449 U.S. 368 (Supreme Court, 1981)
Bender v. Williamsport Area School District
475 U.S. 534 (Supreme Court, 1986)
Angelo Fiataruolo, Angelo Veno v. United States
8 F.3d 930 (Second Circuit, 1993)
Ron Nystrom v. Trex Company, Inc. And Trex Company, LLC
339 F.3d 1347 (Federal Circuit, 2003)
Pause Technology LLC v. Tivo Inc.
401 F.3d 1290 (Federal Circuit, 2005)
Enzo Biochem, Inc. v. Gen-Probe Inc.
42 F. App'x 439 (Federal Circuit, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
414 F.3d 1376, 75 U.S.P.Q. 2d (BNA) 1602, 2005 U.S. App. LEXIS 14084, Counsel Stack Legal Research, https://law.counselstack.com/opinion/enzo-biochem-inc-v-gen-probe-inc-cafc-2005.